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ABSTRACT 
The distribution of BRCA1 and BRCA2 germ line mutations in breast/ovarian cancer 
families varies among different populations, which typically present a wide spectrum 
of unique mutations. Splicing mutation 5272-1G>A of BRCA1 and frameshift mutation 
5374delTATG of BRCA2 are highly prevalent mutations in Castilla-León (Spain), 
accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, 
respectively. To test the presence of founder effects, nine Spanish 5272-1G>A and 
thirteen 5374delTATG families were genotyped with polymorphic markers linked to 
BRCA1 or BRCA2.  All the 5272-1G>A families shared a common haplotype in eight 
markers (1.1 Mb region) and the mutation age was estimated in 15 generations 
(~380 years). A conserved haplotype associated to 5374delTATG was observed in 
four markers (0.82 Mb). The mutation occurred approximately 48 generations ago 
(~1,200 years). Each mutation likely arose from a common ancestor that could be 
traced to a small area of Castilla-León and expanded to other Spanish regions. They 
can have significant impact on the clinical management of asymptomatic carriers as 
well as on the genetic screening strategy to be followed in populations with Spanish 
ancestries. 
 
Keywords: BRCA1; BRCA2; Breast cancer; ovarian cancer; founder mutations  
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INTRODUCTION 
Breast cancer is a multifactorial disease caused by interactions between genetic and 
non-genetic factors. Among 5-10% of all breast and ovarian cancers are considered 
hereditary, and about 30-50% of them are due to mutations in the two major 
susceptibility genes (BRCA1 and BRCA2) (1-3). Approximately 3,500 distinct 
sequence variants have been described in the BIC database, of which more than 
1,700 are pathogenic. Mutations are scattered along the entire coding regions and 
intronic flanking sequences of both genes. The frequency and incidence of mutations 
in these genes varies depending on the geographical area or the ethnic group. 
However, several alterations have been identified in particular populations due to 
founder effects. To describe a recurrent mutation as a potential founder mutation, it is 
important to show that the mutation occurred only once in an ancestral individual or 
common ancestor. To distinguish between single and multiple historical occurrences 
of the same mutation, it is necessary to genotype DNA variants that are close 
enough to the mutation to cosegregate together through numerous generations, with 
little or no separation by meiotic recombination. Likewise, the identification of 
recombinant polymorphic markers in this study it is essential to estimate the number 
of generations since the mutation occurred. 
Founder mutations have been described in individuals of distinct ancestries (4) 
including those observed in Ashkenazi Jews (187delAG and 5382insC of BRCA1 and 
6174delT of BRCA2) (5), Iceland (BRCA2 995del5) (6), and Portugal (BRCA2 
c.156_157insAlu) (7,8), and other populations (9-11). In the Spanish population 
mutations, 330A>G of BRCA1 from Northwestern Spain and 9254delATCAT from the 
Mediterranean region were described as founder mutations (12,13). The identification 
of founder mutations contributes to reduce the time and cost of the analysis providing 
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an efficient design of the mutational screening protocols and genetic counselling in a 
specific population (14,15).  
Since 1998, we have scanned for mutations the BRCA1 and BRCA2 genes in low to 
high risk breast/ovarian cancer patients within the Hereditary Breast and Ovarian 
Cancer (HBOC) prevention program of Castilla-León (Spain). In previous works we 
found that 65 out of 459 unrelated families carried a pathogenic mutation (23 BRCA1 
and 42 BRCA2) (16-18). We have completed the analysis in another 227 BOC 
families totalling 686 scanned families, where 104 positive families (15.2%; 38 
BRCA1 and 66 BRCA2) were identified. The most frequent mutation of BRCA1 was 
5272-1G>A (c.5153-1G>A according to the Human Genome Variation Society –
HGVS- nomenclature) that was found in seven unrelated families (19) while 
3036delACAA (HGVS nomenclature c.2808_2811delACAA) and 5374delTATG 
(HGVS c.5146_5149del4) were the most prevalent of BRCA2, that were detected in 
12 and 9 families, respectively. 
BRCA1 5272-1G>A has been reported only five times in the BIC database or in 
Spanish families (20,21). This mutation causes an aberrant splicing of exon 19 by 
deletion of the first nucleotide, which generates a frameshift and a premature stop 
codon (20,21). The frameshift deletion 5374delTATG truncates the BRCA2 protein at 
codon 1723 and was described by our group for the first time although it has also 
been reported by other groups (17,20,22,23). By contrast, the 3036delACAA 
mutation has been described worldwide in many populations and is the second 
recurrent pathological mutation in the BIC database ranking. A previous work 
suggested that it may have multiple different origins (24). 
In order to determine the presence of possible founder effects of mutations BRCA1 
5272-1G>A and BRCA2 5374delTATG in Castilla-León we proceeded to study the 
 5 
haplotypes associated with them in our families and another two 5272-1G>A and four 
5374delTATG families that were recruited from other Spanish regions. 
.  
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MATERIALS AND METHODS 
Patients 
Breast and/or ovarian cancer patients from Castilla-León were selected according to 
the following criteria (16): (I) One breast cancer (BC) ≤ 40 y, (II) two BC, one of them 
≤ 50, (III) three or more BC, (IV) BC and ovarian cancer (OC) in the same family or 
patient, (V) one male breast cancer, (VI) bilateral BC, (VII) two OC, and (VIII) 1 BC + 
familial aggregation of other types of cancer. A total of 686 families that fulfilled the 
selection criteria were recruited for BRCA screening. A written informed consent was 
obtained from all patients. 
BRCA1 and BRCA2 mutational analysis 
Genomic DNA was isolated from peripheral blood lymphocytes by standard 
procedures. The complete coding sequences and the intron-exon boundaries of both 
genes were analyzed by Conformation Sensitive Gel Electrophoresis (CSGE) and 
Heteroduplex Analysis by Capillary Array Electrophoresis (HA-CAE) (25-27) 
(Supplemental Figures 1 and 2), and subsequent DNA sequencing of anomalous 
patterns using the BigDye Terminator Sequencing Kit v3.1 (Applied Biosystems, 
Foster City, USA). In order to avoid any confusion, designation of mutations was 
according to the BIC database 
(http://research.nhgri.nih.gov/projects/bic/Member/index.shtml); cDNA accession 
numbers were U14680 (BRCA1) and U43746 (BRCA2). Also, detection of large 
genomic rearrangements in BRCA1 was performed in high risk patients (criteria III 
and IV) with previous negative BRCA test. Multiplex ligation-dependent probe 
amplification (MLPA) of BRCA1 (P002-BRCA1; MRC-Holland, Amsterdam, The 
Netherlands) was carried out according to the manufacturer’s instructions. 
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BRCA1 5272-1G>A and BRCA2 5374delTATG families. 
A total of 22 HBOC families harbouring either 5272-1G>A or 5374delTATG were 
recruited from the Genetic Counselling Unit of Hospital General Yagüe (Burgos) and 
other five Spanish centres (Hospital de Cruces, Barakaldo; Fundación Pública 
Galega Medicina Xenómica-SERGAS, Santiago de Compostela; Hospital 
Universitario San Carlos, Madrid; Hospital La Fe, Valencia; and Instituto Catalán de 
Oncología, Barcelona). Information about the number and type of cancers in each 
family, age of diagnosis, age of death or current age and geographical origin were 
collected. DNA samples were obtained from at least one affected member except for 
one family, where patient sample was not available. 
Microsatellite and SNP analysis 
Six short tandem repeats (STR) markers spanning a 3.8 Mb interval of chromosome 
17 were used for haplotype analysis of 5272-1G>A individuals, two of them were 
intragenic (D17S855 and D17S1323) and four flanked the BRCA1 locus (D17S800, 
D17S1185, D17S1325 and D17S579). Four additional SNPs of the BRCA1 gene 
were typed by HA-CAE and subsequent direct sequencing (2731C>T, 3232A>G, 
4604-63C>G and 5194-53C>T). 
Haplotype analysis for 5374delTATG families was performed using seven STRs 
(D13S260, D13S1699, D13S1698, D13S171, D13S1767, D13S1695 and D13S1694) 
flanking the BRCA2 gene that encompassed a region of 1.34 Mb of chromosome 13 
and loci were ordered according to the Ensembl map (www.ensembl.org). SNP 
1342C>A of BRCA2 exon 10 was also genotyped. Primer sequences were obtained 
from the Ensembl database and standard PCR conditions were used. One primer of 
each pair was labelled with FAM or HEX fluorochromes. The amplification products 
were separated on an ABI 3130 Genetic Analyzer and analyzed with the 
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GeneMapper v3.7 software (Applied Biosystems). STR allele designation was 
arranged according to Supplemental Tables 1 and 2. These markers were genotyped 
in index cases and additional family members, and 75 control individuals to estimate 
allele frequencies. 
Haplotype construction and estimation of mutation age. 
Haplotype construction was performed manually or with the program PHASE 
v2.1 (28) based on the genotypes obtained of index cases and relatives and control 
individuals. Several methods for dating mutations have been developed, all of them 
based on the calculation of the linkage disequilibrium between the disease allele and 
linked markers (29,30). The age in generations for both mutations was calculated 
with the equation G=logδ/log(1-θ), where δ represents the linkage disequilibrium 
measure between the mutation and every one of the closest recombinant 
microsatellite marker and θ is the recombination fraction between a marker and the 
gene (29). 
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RESULTS 
BRCA1/2 pathological mutations in Castilla-León. 
The BRCA1 and BRCA2 genes of 686 unrelated families (1067 samples 
including probands and family members) were scanned for mutations. We identified 
104 families carrying a deleterious mutation, 38 BRCA1 (BRCA1+) and 66 BRCA2 
positive families (BRCA2+), that accounted for 15.2% of positive families in our 
region. Four recurrent mutations in BRCA1 and eight in BRCA2 contributed to the 
52.63% and 59.1% of all deleterious mutations of each gene, respectively, that may 
reflect the presence of region-specific founder effects. The most frequent mutation of 
BRCA1 was 5272-1G>A, found in seven  BRCA1+ families (18.4%), whereas, 
3036delACAA (12 BRCA2+ families; 18.1%) and 5374delTATG (nine families; 
13.6%) were the most prevalent alterations of BRCA2.  
Haplotype generation and age estimation of 5272-1G>A 
We typed seven families with the BRCA1 5272-1G>A mutation of the east of 
Castilla-León region and two additional Spanish positive families from the Basque 
Country and Valencia, one of them with confirmed origin in our region. This mutation 
is responsible of twelve breast cancer cases (two patients with bilateral BC) and two 
ovarian cancer cases (both with BC, too). The mean age of diagnosis is 49.9 years 
ranging from 23 to 76 years for breast cancer and 45.5 years for ovarian cancer 
(Table 1). A total of 24 family members, 19 of them positive carriers, were available 
to establish the core haplotype.  
We constructed the haplotype with six STR markers and four SNPs (Table 2; 
Figure 1). The DNA change 5194-53C>T were the most informative SNP as the 
disease-associated allele is only present in 12% of controls (Table 2). Six of the nine 
families share the haplotype 6-17-T-G-7-C-T-6-8-11. In three families (117, 178 and 
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V-4), the disease-associated haplotype showed a recombination in one of the most 
distal flanking markers, D17S800 or D17S579. This common haplotype was found 
neither 150 control chromosomes nor non-carrier relatives. Furthermore, the 
frequencies of STR alleles of the core haplotype were lower than 15% in the control 
chromosomes, except for the D17S1323 microsatellite where the allele 6 was also 
the most prevalent in controls (63%).  
The linkage disequilibrium measures (δ) between the mutation and each of the 
recombinant microsatellite markers D17S800 and D17S579 were calculated as δ= 
0.7174 and δ= 0.7685, respectively. The recombination fraction (θ) was determined 
from the physical distance between the mutation and each of the markers, resulting 
0.0215 cM for D17S800 and 0.017 cM for D17S579. According to these data the 
mutation 5272-1G>A arouse approximately between 15.28 and 15.36 generations 
ago or 382-384 years assuming 25 years per generation. 
Haplotype generation and age estimation of 5374delTATG. 
In the same way, BRCA2 5374delTATG mutation was detected in nine 
unrelated families from our region. Also, four Spanish families collected from Galicia, 
the Basque country, Catalonia and Madrid participated in this study. Clinical 
characteristics of these families are shown in Table 1. Among the carriers there were 
twenty breast cancer cases (four of them bilateral and one male BC), two OC, four 
gastric and three prostate cancers among others (Table 1). The average age of 
female BC cases was 47.1 years (ranging from 28 to 74 years old) and 67 years for 
OC. A total of 43 family members, 31 of them positive carriers, were used to 
construct the disease-associated haplotype. 
Eight of the thirteen families carried a common haplotype associated to this 
mutation (9-2-12-2-C-3-6-5-3) (Table 3; Figure 2). This shared haplotype included six 
 11 
markers covering 0.820 Mb; but D13S1698 or D13S1695 markers recombined in the 
rest of the families. For these markers the linkage disequilibrium measures obtained 
were δ= 0.9070 for D13S1698 and δ= 0.74126 for D13S1695. Therefore, the age of 
the mutation was estimated around 48 generations (46.43-48.85), hence the 
mutation began to spread between 1160 and 1221 years ago (25 years/generation). 
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DISCUSSION  
Reports of founder mutations in cancer predisposing genes are growing day 
by day. Their knowledge permits an efficient screening strategy in each population 
(4,7,31) and they also provide unique opportunities to carry out genotype-phenotype 
correlations. In the Spanish population there are two proved founder mutations: 
BRCA1 330A>G (Galician origin) (13) and BRCA2 9254delATCAT (Mediterranean 
origin) (12). Both mutations are also frequent in our region, accounting for 13.2% of 
BRCA1+ families (5/38) and 7.6% (5/66) of BRCA2+ ones, respectively. Herein we 
provide additional support for another two founder mutations: BRCA1 5272-1G>A 
and BRCA2 5374delTATG. 
Nucleotide substitution 5272-1G>A is a splicing mutation that abolishes the acceptor 
site of intron 18 of BRCA1 but at the same time generates a novel splice site one 
nucleotide downstream (http://www.fruitfly.org/seq_tools/splice.html), and a 
premature stop codon and consequently a truncated protein at position 1728 (20). 
Therefore, it disrupts the essential BRCT domains of the BRCA1 protein (amino 
acids 1649-1736, 1756-1855). The average age at diagnosis was 49.9 years that is 
significantly greater than previously reported for mutations in the BRCA1 gene (~41 
years) (32). One possible explanation could be that mutations of the 3’end of BRCA1 
might have a different age-related expressivity, but other mutations of this region do 
not have a remarkable effect on this parameter, such as 5382insC of Ashkenazi 
origin with an average onset of 41 years (32). Another alternative explanation could 
be that the effect on splicing of 5272-1G>A might modify the expressivity of this 
mutation compared to protein truncating mutations of 3’ exons. Again, other splicing 
mutations of the 3’ end have been reported with even lower age at diagnosis than the 
average of BRCA1 families (e.g. 5271+1G>C [37.7 years] and 5397-1G>T [38.3 
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years]) (33). Further studies of 5272-1G>A families are needed to clarify this issue. 
Among families harbouring this mutation the ratio of breast cancer versus ovarian 
cancer is 6.5:1, which is in agreement with previous reports (34) that justify a lower 
proportion of ovarian cancer associated to mutations in the 3’ region of the gene.  
In East Castilla-León 5272-1G>A mutation was observed in seven unrelated families 
and is the most prevalent BRCA1 mutation (18.4%). Intriguingly, this mutation has 
not been identified in West Castilla-León (35). To date, this mutation has been 
detected in another three Spanish families outside Castilla-León (Figure 3), one of 
them could not be included in this study. We confirmed that family BI-1 (Table 1) also 
came from Burgos, but unfortunately, we could not ascertain the origin of the two 
remaining families. Additionally, this mutation has been reported in four western 
European patients at the BIC database. Seven BRCA1 5272-1G>A families share an 
identical haplotype covering a chromosomal region of 3.8 Mb; the remaining two 
showed recombinations at the most distal markers. Altogether these data indicated a 
recent origin with a common ancestor 15.3 generations ago or 383 years (25 years 
per generation). The poor dispersal of this mutation in the rest of Spanish regions 
might be also attributed to the epidemic diseases that overwhelmed Burgos during 
the 17th century (http://www.artehistoria.jcyl.es/). The presence of this mutation in 
Western Europe (BIC database) might be due to the European wars of the Spanish 
Empire (1516-1714). It would be very interesting to know whether these European 
families have the same core haplotype. By contrast, one of the most frequent BRCA1 
mutations in Spain and worldwide, 187delAG, is absent in our region (16,21).The 
explanation may rely on the effective expulsion of non-converted Jews after the 
Christian “Reconquista” in the 15th century.  
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With regard to BRCA2 5374delTATG, this mutation truncates the BRCA2 
protein at codon 1723 disrupting 3 out of the 8 BRC repeats that interact with RAD51, 
and the entire C-terminal region. The average age at onset of breast cancer was 47.1  
years (range 28-74 years) in agreement with previous works that indicated that 
BRCA2 is associated with an older age at diagnosis of BC (32,36). This mutation is 
also associated with prostate cancer in three pedigrees (Table 1) (37). Conversely, 
another 4-nucleotide deletion only 30 bp upstream (5344delAATA) with a similar 
effect on the protein (stop codon at 1710) (16) is apparently associated with early 
onset BC (average 37.7 years, range 29-55), although the number of cases (6 BC) is 
not significant.  
Since it was reported for the first time by our group in two unrelated families 
(17), we have identified seven more pedigrees, which account for 13.6% of BRCA2+ 
families (Figure 3). Afterwards, it was found in other regions of Northern Spain 
(20,22) or in Hispanic Countries (38). All the collected families shared an ancestral 
haplotype enclosing a 0.82 Mb region. Family 672 showed a recombination event 
between D13S260 and D13S1699. We estimated that this DNA change was 
originated 48 generations ago (about 1190 years), when the Iberian territory 
remained under Islamic dominion, and began the conquest and a repopulation 
process of the region by the Northern Christian kingdoms 
(http://www.artehistoria.jcyl.es/histesp/lugares/272.htm). By this time, Burgos was 
part of the Southern border of the Asturias Kingdom with the Muslim Emirate of 
Cordoba. Thus, it would be also very interesting to know the prevalence of 
5374delTATG in Southern Spain or even in the Maghreb countries, where it might 
hypothetically represent a relevant genetic risk factor although until now full data from 
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these regions have not been published. Its identification in two Chilean families also 
supports the hypothesis that it expanded before the colonization in 1492 (38).  
Both mutations, 5272-1G>A and 5374delTATG, account for around 1 in 6 of 
deleterious mutations of both genes in families from Castilla-León (15.4% of 
BRCA1/2 positive families). Direct screening of these mutations could be undertaken 
as a first step for molecular analysis allowing for a more rapid, accurate and less 
expensive test. In our population, both mutations are initially tested by HA-CAE of the 
corresponding exons (26) that provides clear distinguishable patterns for each 
mutation that is subsequently confirmed by sequencing (see Materials and Methods 
and Supplemental Figures 1 and 2). Moreover, precise estimates of the prior 
probability of a mutation carrier developing cancer should be possible (39).The final 
goal of the genetic testing is to focus on prevention strategies to reduce the risk of 
cancer in asymptomatic carriers. The oncologist recommends annual determination 
of CA-125 (cancer antigen 125); gynecologic and mammographic and/or breast 
magnetic resonance surveillance, transvaginal ultrasonography and lastly, 
prophylactic surgery (bilateral mastectomy, salpingo-oophorectomy) to the BRCA1 
5272-1G>A and BRCA2 5374delTATG asymptomatic carrier women. 
Recommendations for the BRCA2 5374delTATG male carriers included an annual 
breast examination and prostate screening (PSA –Prostate Specific Antigen- and 
digital rectal examination).  
Previous works have indicated that mutational events are not random and occur at 
physiologically stable DNA secondary structures called hairpin-loops (40,41). 
Interestingly, 5374delTATG is placed in the single-stranded portion of a hairpin-loop 
structure that is more vulnerable to spontaneous mutagenesis (Supplemental Figure 
3) (40,41). Mutation 5272-1G>A is located in double-hairpin structure where the 
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nucleotide 5272-1 is apparently a hotspot with two different changes: G to A and G to 
C. Furthermore, another important BIC mutations surrounding both, BRCA2 
5298A>C and 5301insA (39 and 29 BIC entries, respectively), and BRCA1 5277A>G 
(15 BIC entries) are located in these “mutagenic” structures. These data suggest that 
most important mutations of the BRCA genes could have been generated by this 
mechanism.  
In conclusion, each of these mutations likely arose from a common ancestor that 
could be traced to a small area of the provinces of Burgos and Palencia (539.253 
inhabitants; shadowed in Figure 3). Both mutations are responsible for 27.6% of the 
58 BRCA+ families from this specific area  and the 5272-1G>A mutation alone is 
carried by 39% of BRCA1+ families (7/18). Moreover, the constant migratory 
movements of the Castilla-León population 
(http://www.ine.es/inebmenu/mnu_cifraspob.htm) might also have spread these 
mutations to Central-Southern Spain and even Latin American countries where they 
might represent important cancer risk alleles. Finally, founder mutations are useful to 
design an efficient mutational screening in a specific population, and estimating the 
age of the more recent common ancestor may improve our understanding of the 
population genetics of HBOC. The identification of founder effects will also facilitate 
the discovery of other genes and/or lifestyle modifiers that could elucidate the 
phenotypic heterogeneity as well as differences in penetrance and expression in 
families carrying the same mutation. 
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FIGURE LEGENDS 
 
 
Figure 1. Segregation of the haplotype linked to mutation 5272-1G>A in family 
CYL117. Ancestral haplotype is boxed; the index case is indicated by an arrow; black 
circles indicate disease positive relatives and asymptomatic carriers are shown as 
half-filled circles. Some microsatellites were not analyzed (n.a.) because no more 
DNA sample was available.  
 
 
Figure 2. Segregation of the haplotype linked to mutation 5374delTATG in 
family CYL239. Ancestral haplotype is boxed; the index case is indicated by an 
arrow; black circles indicate disease positive relatives and an asymptomatic carrier 
male is shown as a half-filled square. The asterisk indicates a phenocopy not 
associated with this mutation. Some microsatellites were not analyzed (n.a.) because 
no more DNA sample was available.  
 
Figure 3. Geographic distributions of the families carriers of the two founder 
mutations in Spain (left) and Castilla-León (right). 5272-1G>A families are 
represented with black boxes and 5374del4 are shown as black circles. Most families 
are concentrated in a small area comprising part of the provinces of Burgos and 
Palencia that are shadowed (right). 
 
Table 1. Clinical characteristics of families. 
Family  
Proband 
Cancer cases in relatives (age at onset) b Age a Selection criteria 
5272-1G>A 
117 49 III 2 BC (66, 76); 1 CRC (60)  
175  47OC-51 III 3 BC (29, others >50); 1 esophagus (62); 1 tongue (53) 
178  27-47bi VI 2 OC (57, 57c); 1 CRC + leukemia (81+83c); 1 Gastric (64) 
302 44 III 1 BC (46c); 1 OC (47c) 
359  42-44OC III 2 BC (45c, 46); 1 gastric (82); 1 hepatic (47c)  
609  54 VIII 1 BC (80c); 1 esophagus (61c); 1 bladder (61c)  
663  46-46bi II 1 BC (51) 
BI-1  23 III 2 BC (53c,64c.); 1 lung (65c); 1 gastric (68c) 
V-4  48 II 1 BC+OC (59BC+65OCc);1 lung; 1 gastric 
5374delTATG 
126 68 III 3 BC (43c, 66, 87c), 2 lung (55c, 68) 
135 29  III 2 BC (34, 47) 
239 28  III 3 BC (31c, 58, 50) 
287 50 III 2 BC (42, 42c); 1MBC (71PR+78BC); 1 PR (60c)  
353 0 (59) II 2 BC (32c, 58c) 
534 40  II 1 BC (59) 
625 58-66bi,c II 1 BC (40c), 1 gastric (70c) 
672 44c III 3 BC (42bi, 49c, 83), 2 OC (35, 63)  
674 67OC III 2 BC (58, 63c), 1 OC (56c) 
Gal 28-38bi II 1 BC (42c); 2 gastric (60c, 66c); 1 PR (70c) 
M-179 49 II 1 BC (74-75bi); larynx (37c); gastric (45c); hepatic (65c); abdominal (64c) 
B-6 40-44bi III 2 BC (39, 56); 1 bladder (85c), 1 lung 
BI-3 67OC III 5 BC (28c, 42, 44, 46c, 52); 1MBC (47BC+50PR,c); 1 PR; 2 CRC (50c, 75c); larynx (47c) 
Types of cancer: BC, breast cancer; OC, ovarian cancer; bi, bilateral; MBC, male breast cancer; PR, prostate cancer, CRC; colorectal cancer. 
a In family 353 the proband is healthy; within brackets is the current age. Probands of families 625 and 672 died at the age of 68 and 52, respectively. 
b Carrier relatives are shown in bold type. 
c Deceased patients. 
 
Table 2.  Haplotype analysis of BRCA1 5272-1G>A families. 
Marker Position (Mb) 
FAMILY * CONTROLS 
(75) 117  (8) 
175  
(1) 
178 
(3) 
302 
 (1) 
359 
 (4) 
609  
(1) 
663 
 (2) 
BI-1  
(2) 
V-4 
(2) 
D17S800 2.150 6 3/6  5 6/6 6 5/6 6 6 5 6 (13%) 
D17S1185 0.655 17 13/17 17 15/17 17 11/17 17 17 17 17 (9%) 
2731C>T exon 11 T C/T T C/T T T/T T T T T (48.3%) 
3232A>G exon 11 G A/G G A/G G G/G G G G G (48.3%) 
D17S855 intron 12 7 2/7 7 6/7 7 7/8 7 7 7 7 (10%) 
4604-63C>G intron 14 C C/C C C/C C G/C C C C C (51%) 
5194-53C>T intron 17 T C/T T C/T T C/T T T T T (12%) 
BRCA1 5272-1G>A  
D17S1323 intron 20 6 6/6 6 6/6 6 3/6 6 6 6 6 (63%) 
D17S1325 0.430 8 8/14 8 8/13 8 8/12 8 8 8 8 (2%) 
D17S579 1.700 7 9/11  11 11/12 11 3/11 11 11 10 11 (2%) 
* The number of relatives tested is between brackets. Shared alleles are in bold type. The allele’s frequencies were 
calculated from 75 controls. 
  
 
Table 3. Haplotype analysis of 5374delTATG-BRCA2 families. 
Marker Position (Mb) 
Castilla-León (CYL) FAMILIES*  NON-CYL FAMILIES* CONTROLS 
(75) 126 
(8) 
135 
(5)  
239 
(6) 
287 
(4) 
353 
(1) 
534  
(4) 
625 
(4) 
672 
(3) 
674 
(2) 
 
 
GAL 
(3) 
M179 
(1) 
B6 
(1) 
BI-3 
 (4) 
D13S260 -0.480 8 9 9 9 8/9 9 9 6 9   9 8/9 8/9 11 9 (18%) 
D13S1699 -0.310 2 2 2 2 2/2 2 2 2 2   2 2/2 2/3 2 2 (56%) 
D13S1698 -0.210 12 12 12 12 3/12 12   12 4   12  12 10/12 12/11 12 12 (23%) 
D13S1697 -0.050 2 2 2 2 2/2 2 2 2 2  2 2 2/3 2 2 (78%) 
1342C>A exon 10 C C C C C/A C C C C  C C C C C (28%) 
BRCA2 5374delTATG 
D13S1701 0.230 3 3 3 3 3/4 3 3 3 3  3 2/3  3/6 3 3 (27%) 
D13S171 0.340 6 6 6 6 6/8 6 6 6  6  6 6/8 6/7 6  6 (41%) 
D13S1695 0.610 5 5 5 5 5/11 5 5 5 5  5 6/7 6/6 6 5 (6%) 
D13S1694 0.860 3 3 3 3 3/3 3 3 3 3   3 3/3 3/4 3 3 (43%) 
*The number of relatives tested is between brackets. Shared alleles are in bold type. The allele’s frequencies were calculated from 75 
controls.  
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Supplementary Figure S1. GeneMapper screenshots of BRCA1‐exon 19 detected by HA‐CAE. Scan points are 
in  x‐axe and  relative  fluorescent units  (RFU)  are    in  y‐axe.  (A) Normal pattern.  (B) 5271‐1G>A pattern.  (C) 
Sequence chromatogram of exon 19 where the nucleotide substitution is shown. 
A B
C
TTTTCTATGATCTCTTTA A GGGTGACCCAGTCTATTAAAGAAA
TTTTCTATGATCTCTTTA G GGGTGACCCAGTCTATTAAAGAAA
Supplementary Figure S2. GeneMapper screenshots of BRCA2‐fragment 11R detected by HA‐CAE. Scan points are  in x‐
axe  and  relative  fluorescent  units  (RFU)  are  in  y‐axe.  (A)  Normal  pattern.  (B)  5374delTATG  pattern.  (C)  Sequence 
chromatogram of Fragment 11R of exon 11 where the deletion is boxed. 
A B
T G T A G G A A A T T A T  T T G TATGAAAATAA… wt
AAAATAATTCA… del
C
Supplementary  Figure S3. DNA  secondary  structure of  regions  surrounding mutations 5374delTATG  (A) and 5272‐1G>A  (B) obtained with  the program Quikfold
(http://dinamelt.bioinfo.rpi.edu/quikfold.php; Markham &  Zuker,  2008). Although  other  secondary  structures  are  possible,  only  the most  stable  thermodynamic 
structures are shown. A) Nucleotides of founder mutation 5374delTATG (shown in red) are placed in a hairpin loop. Other important mutations from the BIC database 
are  indicated. The most prevalent mutations of  this  region are placed  in  another hairpin  loop  (5298A>C  and 5301insA) or  anomalous  structures with mispaired
nucleotides  (e.g. 5358delTGTA). Another mutations placed  in bulge  loops are  shown  in  the  figure. B) Double hairpin‐loop  structure of DNA  segment  surrounding 
mutation 5272‐1G>A (shown in red). Upper case, exonic sequence; lower case, intronic sequence. This nucleotide is also affected by another mutation (5272‐1G>C). 
Another six BIC mutations of this DNA segment are shown. Origin of all of  these mutations seems  to be correlated with  their presence  in specific DNA secondary 
structures (single‐stranded DNA, bulge loops or, specially,hairpin‐loops) that are particularly vulnerable to mutagens. 
c.5298A>C (p.K1690N)
(39 BIC records)
c.5301insA (29 BIC records)
mispairing
Bulge loop
Hairpin loop
c.5335G>T
(p.E1703X)
c.5358delTGTA (7 BIC records)
c.5374_5377delTATG
c.5323G>A
(p.D1699N)
c.5324A>G
(p.D1699G)
5298A>C (p.K1690N
5335G>T
delTATG
5323G>A
5324A>G
c.5281 c.5401
A)
5272-1G>A
5272-1G>C / 6 BIC entries
5277A>G (p.T1720A)
15 BIC entries
5272G>C5273G>T
c.5272-11 c.5296
B)
Double hairpin-loop
Supplementary table S1. Microsatellite markers linked to the BRCA1 gene that have been typed in CyL population in this 
study. Allele frequencies were calculated in 150 control chromosomes.   
 
D17S800 D17S1185 D17S855 D17S1323 D17S1325 D17S579 
Frequency Size Allele Frequency Size Allele Frequency Size Allele Frequency Size Allele Frequency Size Allele Frequency Size Allele 
0.07  165 7 0.03 197 18 0 133 12 0.03 147 8 0.01  180 20 0.12  111 13 
0.13  167 6 0.09  201 17 0.01 141 11 0.07  149 7 0.01  184 19 0.09  113 12 
0.53  169 5 0.16  205 16 0.01 143 10 0.63  151 6 0.01  186 18 0.02  115 11 
0.04 171 4 0 207 14 0.07 145   9 0.03  153 5 0.04  190 17 0.02  117 10 
0.16 173 3 0.11 209 15 0.20 147   8 0.07 155 4 0.05  192 16 0.04  119 9 
0.06 175 2 0.18  213 13 0.10  149   7 0.14 157 3 0.02  194 15 0.09  121 8 
0.01 177 1 0 215 12 0.18  151   6 0.03  159 2 0.30  196 14 0.22  123 7 
   0.22  217 11 0.22  153   5 0 161 1 0.18 198 13 0.22  125 6 
   0.02 219 10 0.15  155   4   0.10  200 12 0.11  127 5 
   0.12 221 9 0.05  157   3   0.05  202 11 0.02  129 4 
   0.02  223 8 0.01 159   2   0.07  204 10 0.02 131 3 
   0.03  225 7 0 161   1   0.03 206 9 0.02 133 2 
   0.01  227 6     0.02  208 8 0.01  135 1 
   0.01 231 5     0.01  210 7    
   0 235   4     0.01  212 6    
   0 237   3     0.01 214 5    
   0.03  239 2     0.05  216 4    
   0 243   1      0.01 218 3    
         0.01 222 2   
        0.01  228 1    
The size of alleles is in bp. The most frequent allele in controls is in bold type whereas the alleles segregating with the disease in 5272-1G>A 
families are in italics.  Alleles that show frequency 0 are present in carrier families but not in the control samples. 
 
Supplementary table S2. Microsatellite markers linked to the BRCA2 gene that 
have been typed in CyL population in this study. Allele frequencies were 
calculated in 150 control chromosomes.   
 
D13S260 D13S1699 D13S1698 D13S1697 
Frequency Size Allele Frequency Size Allele Frequency Size Allele Frequency Size Allele
0  143 13 0.01  140 4 0 153 15 0 217 4
0 149 12 0.38  144 3 0 155 14 0.19  221 3
0.09  151 11 0.56  148 2 0.08  157 13 0.78 225 2
0.03 153 10 0.05  152 1 0.23  159 12 0.03  229 1
0.18 155 9   0.08  161 11   
0.28  157 8   0.27  163 10   
0.05 159 7   0.03  165 9   
0.16 161 6   0.03 167 8   
0.16  163 5   0.05  169 7   
0.02  165 4   0.01  171 6   
0.02  167 3   0.04  173 5   
0.01  169 2   0.10  175 4   
0 171 1   0.06  177 3   
     0.01  179 2   
     0.01  183 1    
D13S1701 D13S171 D13S1695 D13S1694 
Frequency Size Allele Frequency Size Allele Frequency Size Allele Frequency Size Allele
0.01  280 8 0.09  191 8 0.03 237 12 0.01 224 7
0.02  284 7 0.34 193 7 0.02  241 11 0.26  228 6
0.13  288 6 0.41  195 6 0.08  243 10 0.04 230 5
0.21  292 5 0.01  197 5 0.01  247 9 0.12  232 4
0.28 296 4 0 201 4 0.01 249 8 0.43  234 3
0.27  300 3 0.01  203 3 0.40 251 7 0.13 236 2
0.07  304 2 0.14  205 2 0.30 253 6 0.01  238 1
0.01  308 1 0 207 1 0.06 255 5   
     0.03  257 4    
     0.03  259 3   
     0.02 261 2    
     0.01 263 1    
The size of alleles is in bp. The most frequent allele in controls is in bold type whereas the 
alleles segregating with the disease in 5374_5377delTATG families are in italics. Alleles that 
show frequency 0 are present in carrier families but not in the control samples. 
 
